Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs)

NEXT STORY
Aleafia Health Increases Strategic Investment in Australian LP CannaPacific
PREV STORY
Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Delcath Issues Letter to Shareholders

NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional ...

author_avatar
NASDAQ Market News

T2 Biosystems Receives FDA Clearance to Market T2Bacteria Panel for Detection of Sepsis-Causing Pathogens

First FDA-cleared test to identify sepsis-causing bacteria direct from whole blood Cuts time to ...

author_avatar
NASDAQ Market News

Qu Biologics invited to present Research Data at International Scientific Meetings

VANCOUVER, British Columbia, May 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical ...

author_avatar
NASDAQ Market News